In univariate analysis, the effects of risk factors such as gender, age, blood group, BMI of donors and patients, gender parity, CMV reactivation in neutropenia phase and within 30 days post‐transplant, ABO blood group matching status, diagnosis, number and timing of injected G‐CSF unit after HSCT (daily or bidaily), chemotherapy type, the interval between diagnosis to HSCT, glucose level, and disease status before HSCT on early neutrophil and platelet engraftments were examined. The gene discussed is CSF3; the disease is Decreased total neutrophil count.